The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 08, 2020

Filed:

Aug. 11, 2015
Applicants:

Agency for Science, Technology and Research, Singapore, SG;

National University of Singapore, Singapore, SG;

National University Hospital (Singapore) Pte Ltd, Singapore, SG;

Inventors:

Heng-phon Too, Singapore, SG;

Lihan Zhou, Singapore, SG;

Ruiyang Zou, Singapore, SG;

Khay Guan Yeoh, Singapore, SG;

Bok Yan So, Singapore, SG;

Feng Zhu, Singapore, SG;

Wei Peng Yong, Singapore, SG;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); G16B 25/00 (2019.01); G16B 20/00 (2019.01); G01N 33/574 (2006.01); G16H 50/20 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); G01N 33/57407 (2013.01); G16B 20/00 (2019.02); G16B 25/00 (2019.02); G16H 50/20 (2018.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/50 (2013.01);
Abstract

Disclosed are methods of determining the likelihood of a subject having or developing a gastric cancer. The methods comprise measuring the expression level of at least one miRNA having at least 90% sequence identity with an miRNA as described herein in a non-cellular biofluid sample obtained from the subject, wherein differential expression of miRNA expression in the sample obtained from the subject, as compared to a control, may be indicative of the subject having gastric cancer and wherein the miRNA may be either an miRNA listed as 'up-regulated' or an miRNA listed as 'down-regulated'. Also disclosed is a method of determining the likelihood of a subject having or developing a stage of a gastric cancer.


Find Patent Forward Citations

Loading…